Selective Inhibition of<i>N</i>-Formylpeptide-Induced Neutrophil Activation by Carbamate-Modified Peptide Analogues
Claudia K. Derian(Johnson & Johnson (United States)), Alan J. Fischman(Shriners Hospitals for Children), Michael J. Beblavy(Massachusetts General Hospital), Gary Bridger, Howard F. Solomon, John Higgins(Massachusetts General Hospital), Daniel J. Kroon, Marilyn C. Pike(Bethesda Hospital), Rosemary J. Santulli(Johnson & Johnson (United States))
Cited by 61
Related Papers
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist
|Blood|2003|717
Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2
|Circulation|2002|652
Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study
|Journal of Clinical Oncology|2009|507